Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer (SKINUX)
Pre-emptive Cycline Treatment on Cetuximab-induced Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With an Intensified FOLFIRI.
Sponsor: Institut Cancerologie de l'Ouest
Terminated
The study stopped due to a lack of recruitment
Other terminated trials from Institut Cancerologie de l'Ouest
Other Colorectal Cancer Metastatic trials with similar outcome
A NA clinical study on Colorectal Cancer Metastatic and Skin Toxicity, this trial is terminated or withdrawn. The trial is conducted by Institut Cancerologie de l'Ouest and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Apr 2020 — Jan 2021 [monthly]
Terminated NA
Status: Unknown Status → Terminated · Phase: PHASE3 → NA
▶ Show 3 earlier versions
-
Feb 2020 — Apr 2020 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Feb 2020 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut Cancerologie de l'Ouest
For direct contact, visit the study record on ClinicalTrials.gov .